EDITORIAL

The Scare of Adventitious Agents in Therapeutic Products
Adventitious agents are a class of living contaminants of exogenous origin that may get introduced during production of biotherapeutic products. These include viruses, bacteria, fungi, mycoplasma, transmissible spongiform encephalopathies (TSE), and other such entities, many of which can propagate to high titers. The contamination could be introduced via raw materials, cell line development, or any other unit operation that is used in the production process.
Recent examples of viral outbreaks in human populations include the West Nile virus, monkey pox, and severe acute respiratory syndrome (SARS). Bovine spongiform encephalopathy (BSE), commonly known as mad cow disease, gave quite a scare between 1987 and 2009. Obviously, these need to stay out of the bioreactors used to produce biopharmaceuticals, and need to be eliminated from donor pools used to make plasma-derived medicines. The importance of careful monitoring of these contaminants as well as the need to ensure that the final product is free of these agents cannot be emphasized enough (1) . Several ICH guidelines deal with this subject (Q5A and Q5D), as well as regional guidance documents.
The Parenteral Drug Association (PDA) has been a leading organization in holding meetings and discussions around this topic. PDA Technical Reports (such as TR21, TR23, TR25, TR41, TR47, TR50) offer a unique collection of best practices in how industry needs to approach these adventitious agents. These documents have been of tremendous value to the pharmaceutical industry and have served the basis for creation and implementation of the internal quality systems that can effectively deal with these issues. In view of the importance of this topic to the community, the PDA Journal plans to continue maintaining it as one of our focus areas and bringing cutting-edge approaches and technologies to this forum. We look forward to receiving more contributions in this area and maintaining our leadership in it.
